| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/04/2004 | US6730664 The side-effects of chemotherapy are suppressed or reduced |
| 05/04/2004 | US6730661 Non-digestible dextrans, hydrolysed (galacto)mannans and/or hydrolysed (gluco)mannans; reduce the uptake of high molecular weight substances, allergens and microorganisms through the intestinal wall |
| 05/04/2004 | US6730660 Peritoneal dialysis solutions with polypeptides |
| 05/04/2004 | US6730658 Stimulation of lymphatic growth with an FLT4 ligand |
| 05/04/2004 | US6730655 Biphenyl diquaternary ammonium compounds |
| 05/04/2004 | US6730537 Coupling arrays of metal, alloy, semiconductor or magnetic clusters scaffold comprising, for example, polynucleotides and/or polypeptides |
| 05/04/2004 | US6730480 Sphingosine kinase enzyme |
| 05/04/2004 | US6730334 Multi-arm block copolymers as drug delivery vehicles |
| 05/04/2004 | US6730331 Topically applied creatine containing composition |
| 05/04/2004 | US6730329 Zinc containing compositions for anti-viral use |
| 05/04/2004 | US6730328 Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity |
| 05/04/2004 | US6730325 Multiparticulate modified release composition |
| 05/04/2004 | US6730324 Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation |
| 05/04/2004 | US6730320 Doxycycline administered in three dosages forms of different release profiles, with cmax being reached in < twelve hours |
| 05/04/2004 | US6730319 Pharmaceutical compositions having depressed melting points |
| 05/04/2004 | US6730313 Adheres to injury site; releases bioactive agent that reduces or prevents further damage |
| 05/04/2004 | US6730308 Tazarotene and alpha hydroxy acid treatment for psoriasis and/or photodamage |
| 05/04/2004 | US6730300 Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications |
| 05/04/2004 | US6730295 Anionic polymers as species specific antibacterial agents |
| 05/04/2004 | US6730288 Lower level of occlusive agent; greater drug skin penetration |
| 05/04/2004 | US6730065 After laser vision correction surgery to optimize pupil size; an imidazoline compound in eye drop form; phentolamine; phenoxybenzamine |
| 05/04/2004 | CA2381031C Local delivery of 17-beta estradiol for preventing vascular intima hyperplasia and for improving vascular endothelium function after vascular injury |
| 05/04/2004 | CA2296178C Human intestinal npt2b |
| 05/04/2004 | CA2248794C Medicament for preventive and treatment for viral infectious diseases |
| 05/04/2004 | CA2235110C Pharmaceutical compositions containing steroid derivatives involved in triggering an immune response |
| 05/04/2004 | CA2213638C Aerosols containing nanoparticle dispersions |
| 05/04/2004 | CA2201631C Liposome-formulations for treatment of viral diseases |
| 05/04/2004 | CA2183234C Agent for prophylaxis and treatment of thromboxane a2-mediated diseases |
| 05/04/2004 | CA2132150C Antiulcer agent and adhesion inhibitor for helicobacter pyroli |
| 05/04/2004 | CA2119756C Process for preparing benzo[b]naphtyridines |
| 05/04/2004 | CA2098148C Process for the preparation of 16-alpha-methyl steroids |
| 05/04/2004 | CA2069600C Fatty acid compositions |
| 04/30/2004 | CA2450643A1 Methods of diagnosing, preventing, and treating early onset of pulmonary hypertension |
| 04/30/2004 | CA2434218A1 Extracts from the marine algae undaria, compositions thereof and method of use |
| 04/30/2004 | CA2418998A1 Applicator and method for applying lanolin to a sore nipple |
| 04/30/2004 | CA2417320A1 Applicator and method for applying lanolin to a sore nipple |
| 04/29/2004 | WO2004036182A2 Methods for monitoring treatment of disease |
| 04/29/2004 | WO2004036181A2 Method of treating neurological diseases and disorders |
| 04/29/2004 | WO2004035798A2 Identification of e2f target genes and uses thereof |
| 04/29/2004 | WO2004035795A1 Vector for anti-hpv vaccine and transformed microorganism by the vector |
| 04/29/2004 | WO2004035738A2 Methylene-bridged selective androgen receptor modulators and methods of use thereof |
| 04/29/2004 | WO2004035736A2 Halogenated selective androgen receptor modulators and methods of use thereof |
| 04/29/2004 | WO2004035656A1 Perfluoropolyether derivatives |
| 04/29/2004 | WO2004035611A2 Peptides binding the phosphatase 2a protein and polynucleotides encoding same |
| 04/29/2004 | WO2004035601A1 Ship 1 modulators |
| 04/29/2004 | WO2004035594A1 Intermediate for producing carboxypeptidase b inhibitor |
| 04/29/2004 | WO2004035588A1 Pyradazine compounds as gsk-3 inhibitors |
| 04/29/2004 | WO2004035587A1 Reverse-turn mimetics and composition and methods relating thereto |
| 04/29/2004 | WO2004035581A1 Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient |
| 04/29/2004 | WO2004035572A1 N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n’-(5-methyl-3-isoxazolyl)urea salt in crystalline form |
| 04/29/2004 | WO2004035548A1 Novel compounds |
| 04/29/2004 | WO2004035543A1 Tetrahydroquinoline derivatives as crth2 antagonists |
| 04/29/2004 | WO2004035536A2 Azo compounds for type i phototherapy |
| 04/29/2004 | WO2004035523A1 Cationic cardiolipin analogs and use thereof |
| 04/29/2004 | WO2004035522A1 Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein |
| 04/29/2004 | WO2004035169A2 Multidimensional protein separation system |
| 04/29/2004 | WO2004035132A2 Compositions and methods for inducing osteogenesis |
| 04/29/2004 | WO2004035096A1 Composition exhibiting stabilised oxidation-reduction properties and method for the stabilisation thereof |
| 04/29/2004 | WO2004035090A1 Gastric acid secretion inhibiting composition |
| 04/29/2004 | WO2004035089A1 Remedy for hormone-dependent cancer |
| 04/29/2004 | WO2004035088A1 Therapeutics/diagnostics for brain tumor |
| 04/29/2004 | WO2004035083A2 Compositions for the treatment of autoimmune disorders |
| 04/29/2004 | WO2004035074A1 Composition for lowering blood glucose level comprising extract of natural product |
| 04/29/2004 | WO2004035071A1 Herbal medicine containing cyclodextrins for the treatment of ear disorders |
| 04/29/2004 | WO2004035067A1 Method for extracting a natural mixture of conjugated equine estrogens that is depleted of non-conjugated lipophilic compounds |
| 04/29/2004 | WO2004035065A1 Hypoglycemic substances containing zinc |
| 04/29/2004 | WO2004035064A1 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
| 04/29/2004 | WO2004035063A1 Pharmaceutical formulation comprising azithrocycin monohydrate |
| 04/29/2004 | WO2004035062A1 Carbohydrate based anti-bacterials |
| 04/29/2004 | WO2004035061A1 Method of administering bisphosphonates |
| 04/29/2004 | WO2004035060A1 Bisphosphonates for the treatment of antheroscleorosis and devices comprising them |
| 04/29/2004 | WO2004035059A1 Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof |
| 04/29/2004 | WO2004035058A1 Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| 04/29/2004 | WO2004035057A1 Therapeutic treatment |
| 04/29/2004 | WO2004035056A1 Use of skca channel blocking drugs for combating parkinson's disease |
| 04/29/2004 | WO2004035055A1 Use of dopamine receptor agonists for the treatment of cutaneous tumors, warts, and scars |
| 04/29/2004 | WO2004035054A1 Transdermal patch for external use comprising fentanyl |
| 04/29/2004 | WO2004035053A1 Neurotrophic factor production promoter |
| 04/29/2004 | WO2004035052A1 Stable solid preparations |
| 04/29/2004 | WO2004035051A1 Lisinopril/lercanidipine combination therapy |
| 04/29/2004 | WO2004035050A1 Use of epothilone derivatives for the treatment of hyperparathyroidism |
| 04/29/2004 | WO2004035049A1 Process for preparing losartan potassium with improved flowability |
| 04/29/2004 | WO2004035048A1 Hepatic fibrosis inhibitor |
| 04/29/2004 | WO2004035046A1 Powder inhalant of sumatriptan and the method of preparation thereof |
| 04/29/2004 | WO2004035045A1 Use of substituted acrylolyl distamycin derivatives in combination with demethylating agents, in the treatment of cancer |
| 04/29/2004 | WO2004035044A1 Dry syrup preparation of procaterol comprising ascorbinic acid and citric acid |
| 04/29/2004 | WO2004035043A1 Clofarabine and platinum chemotherapy combination |
| 04/29/2004 | WO2004035042A1 New use of no donating nsaids |
| 04/29/2004 | WO2004035041A1 Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors |
| 04/29/2004 | WO2004035040A1 Enhancement of alcohol metabolism |
| 04/29/2004 | WO2004035038A1 Therapeutic agent for chronic obstructive pulmonary disease |
| 04/29/2004 | WO2004035037A2 Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators |
| 04/29/2004 | WO2004035036A1 A method of treating vasomotor symptoms comprising a compound having norepinephrine reuptake inhibitor activity and 5-ht2a antagonistic activity |
| 04/29/2004 | WO2004035035A1 Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| 04/29/2004 | WO2004035034A2 Clofarabine and taxane chemotherapy combination |
| 04/29/2004 | WO2004035033A2 Clofarabine and camptothecin chemotherapy combination |
| 04/29/2004 | WO2004035032A2 Pharmaceutical formulations of camptothecine derivatives |
| 04/29/2004 | WO2004035031A2 Treatment of uveal melanoma |
| 04/29/2004 | WO2004035030A2 Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain |
| 04/29/2004 | WO2004035027A1 Pharmaceutical formulation of olanzapine |